Significant Collaboration Transactions - Allonnia LLC Narrative (Details) shares in Thousands, $ in Thousands	1 Months Ended		3 Months Ended	12 Months Ended
	Apr. 30, 2022 USD ($) shares	Mar. 31, 2021 USD ($) shares	Mar. 31, 2023 USD ($) shares	Dec. 31, 2023 USD ($) obligation	Dec. 31, 2022 USD ($) materialRight shares	Dec. 31, 2021 USD ($) obligation shares	Dec. 31, 2020 USD ($) shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Zymergen purchase price consideration				$ 0	$ 19,912	$ 8,760
Loss on equity method investments				2,635	43,761	$ 77,284
Number of allocated performance obligations | obligation						10
Deferred other income					222,600	$ 189,200
Revenue recognized				251,455	$ 477,706	313,837
BiomEdit
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Zymergen purchase price consideration	$ 32,500		$ 4,000
Additional preferred units issued (in shares) | shares			800
Allonnia
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of material rights | materialRight					10
Allocated upfront non-cash consideration				$ 2,500
Number of allocated performance obligations | obligation				10
Fixed non-cash consideration				$ 2,500
Additional non-cash consideration					$ 12,700
Deferred other income				36,100	35,900
Revenue recognized				500	4,300	5,100
Series A Preferred Stock
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares sold (in shares) | shares		1,800
Total Zymergen purchase price consideration		$ 19,500			$ 57,100
Additional preferred units sold (in shares) | shares		7,200					5,400
Number of additional common units received (in shares) | shares					1,900
Series A Preferred Stock | BiomEdit
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares sold (in shares) | shares	6,700
Additional preferred units sold (in shares) | shares	1,500
Allonnia
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Zymergen purchase price consideration						$ 18,500
Number of common units received (in shares) | shares					3,600
Number of additional common units received (in shares) | shares					1,900
Fair value					$ 24,500
Loss on equity method investments					12,700		$ 24,500
Carrying value of the equity method investment					0
Allonnia | Series A Preferred Stock
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares sold (in shares) | shares						1,700	3,000
Total Zymergen purchase price consideration				$ 30,000	$ 200	$ 100	$ 33,000
Additional preferred units sold (in shares) | shares							600
Additional preferred units issued (in shares) | shares					5,400	1,800
Share issued in exchange for the rights to intellectual property (in shares) | shares						180